Company Note

KLCI: 1026.78

Bloomberg: PHRM MK

Results Update

Monday, 11 May2009



enara TA One, 22 Jalan P Ramle 50250 Kuala Lumpur. Malaysia Tel : 603 - 2072 1277 Fax : 603 - 2032 5048

Analyst : TA Research
Tel : 20721277 ext : 1616
e-mail : ikmalhafizi@ta.com.my

Get your facts before you invest



Pharmaniaga Berhad

Pleasant Surprise

Share Price: RM4.20
Target Price: RM3.95
Market Capitalisation: RM449mn
Board: Main

Sector : Pharmaceutical

Recommendation : SELL Stock code : 8133

Key Stock Statistics					
		2007	2008	2009F	
EPS	(sen)	46.8	60.0	60.7	
P/E	(x)	9.0	7.5	6.9	
Div / Share	(sen)	18.0	11.9	18.2	
BV / Share	(sen)	3.4	3.6	4.2	
Issued Capital	(mn)	107			
52 weeks price	(%)	4.04 /	4.04 / 3.10		

Khazanah Berhad - 86%

Per Share Data


Major shareholders

		2007	2008	2009F	2010F
Book Value	(RM)	3.4	3.6	4.2	4.9
Cash Flow	(Sen)	- 1.2	35.0	122.3	180.9
Earnings	(Sen)	46.8	60.0	60.7	100.8
Gross Dividend	(Sen)	18.0	11.9	18.2	30.2
Dividend Yield	(%)	4.3	2.8	4.3	7.2
PER	(x)	9.0	7.5	6.9	4.2
ROE	(%)	15.6	11.1	15.2	21.4

P&L Analysis (RM mil)

	2007	2008	2009F	2010F
Revenue	1184.0	1305.6	1482.8	1646.6
Cost of Revenue	1080.8	1073.8	1366.8	1473.5
EBITDA	103.2	101.5	115.9	173.0
Net Interest	5.4	9.7	7.2	5.4
Depreciation	21.6	21.9	22.3	22.7
Net Profit	50.1	60.0	60.7	100.8

Share Price chart



Source : Bloomberg

1Q09 Results Analysis

				cultivative 10			
YE 31 Decemb	er	4Q08	1Q09	Q0Q%	FY08	FY09	YOY%
Turnover		328.80	313.72	-5%	309.65	313.72	1%
EBIT		26.08	21.36	-18%	29.23	21.36	-27%
Interest Inc/(exp)		-1.59	-1.18	-26%	-1.86	-1.18	-36%
Pretax		24.49	20.18	-18%	27.37	20.18	-26%
Taxation		-6.57	-5.49	-16%	-8.39	-5.49	-35%
Net Profit		17.80	14.52	-18%	18.54	14.52	-22%
EPS	(sen)	16.60	13.57	-18%	17.34	13.57	-22%
EBIT Margin	(%)	7.9%	6.8%		9.4%	6.8%	
Pretax Margin	(%)	7.4%	6.4%		8.8%	6.4%	
Tax Rate	(%)	26.8%	27.2%		30.7%	27.2%	

Cumulative 10

Review

- Pharmaniaga reported 1Q09 net profit of RM14.52mn (or 13.57sen per share) on the back of RM313.72mn revenue.
- The results came well above our estimate as it accounts for 34% of our full year estimate.
- Compared to the preceding quarter, the Group's revenue and net profit contracted by 5% and by 18%.
- The sequential reduction in revenue is partly due to the expiry of some tender sales as well as lower sales to the private sector.
- The company managed to register pedestrian growth of 1% in sales against last year although net profit plunged 22%.





Impact

- We are leaving our FY09 numbers unchanged for now
- We continue to foresee a slowdown in the group's performance. We believe that the better-than-expected 1Q results would not be sustainable throughout the year.

Outlook

• The company has asked for extension of its listing status as it is currently in breach of the public shareholding spread. This issue is still a big concern.

Valuation

 We maintain our target price at RM3.95 as no revision in our numbers is warranted. We base this on a PER multiple of 6.5x. As the potential upside is still now less than 10% - following the sudden jump in share price last week - we are downgrading Pharmaniaga to a SELL.

Disclaimer

The information in this report has been obtained from sources believed to be reliable. Its accuracy or completeness is not guaranteed and opinions are subject to change without notice. This report is for information only and not to be construed as a solicitation for contracts. We accept no liability for any direct or indirect loss arising from the use of this document. We, our associates, directors, employees may have an interest in the securities and/or companies mentioned herein.

This report has been prepared by TA SECURITIES HOLDINGS BERHAD for purposes of CMDF-Bursa Research Scheme ("CBRS") administered by Bursa Malaysia Berhad and has been compensated to undertake the scheme. TA SECURITIES HOLDINGS BERHAD has produced this report independent of any influence from CBRS or the subject company.

For more information about CBRS and other research reports, please visit Bursa Malaysia's website at: http://www.bursamalaysia.com/website/bm/listed_companies/cmdf bursa research scheme/

for TA SECURITIES HOLDINGS BERHAD(14948-M)

(A Participating Organisation of Bursa Malaysia Securities Berhad)

Yaw Chun Soon, Executive Director – Operations